Adventrx Pharmaceuticals, Inc has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its US patent application entitled "Compositions for Delivering Highly Water Soluble Drugs." The patent claims are directed to formulations of vinorelbine bitartrate and provide protection for the company's lead product candidate, ANX-530 (vinorelbine injectable emulsion), or Exelbine.

The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that, upon timely payment of applicable fees, a patent will be issued. Once issued, before taking into account patent term extension, the patent will provide coverage for Exelbine until July 2024.

"The notice of allowance is a positive step toward the future commercialization of Exelbine and we remain on track to submit a New Drug Application for Exelbine this quarter," stated Brian M Culley, chief executive officer of Adventrx.

Adventrx Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.